Cardionomic has raised $9 million in a new round of equity financing, according to an SEC filing posted this week.
The company is developing a neuromodulation therapy device to treat acute decompensated heart failure, a condition in which fluid accumulates in the lungs and other tissues in patients with heart failure.
Money in the round came from four unnamed investors, according to the filing, with the first sale dated on April 17.
The company is looking to raise an additional $608,529 in the round, bringing the total to approximately $9.6 million, according to the SEC filing.
Cardionomic has not yet stated how it plans to spend funds raised in the round.